Xtant Medical Holdings Inc. has reported strong financial results for the second quarter of 2025, with total revenue reaching $35.4 million, marking an 18% increase compared to the same quarter in 2024. This growth is primarily attributed to increased sales in orthobiologics and licensing revenue. The company reported a net income of $3.6 million, a significant turnaround from a net loss of $3.9 million in the prior year quarter. The gross margin also improved to 68.6% from 62.1% in the previous year quarter. Additionally, Xtant Medical has raised its full-year 2025 revenue guidance to a range of $131 million to $135 million, representing a growth of 11% to 15% over the company's 2024 revenue. This updated guidance surpasses the prior forecast of $127 million to $131 million. In recent business developments, Xtant Medical announced definitive agreements to sell its non-core Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine for approximately $19.2 million. This transaction aims to strengthen the company's balance sheet and support the development of its pipeline of advanced biologics.